	US 11,692,169 B2
	Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
Philippe Duchateau, Draveil (FR); and Laurent Poirot, Paris (FR)
Assigned to CELLECTIS, Paris (FR)
Filed by Cellectis, Paris (FR)
Filed on Jul. 27, 2020, as Appl. No. 16/939,466.
Application 16/939,466 is a continuation of application No. 15/118,801, granted, now 10,836,998, previously published as PCT/EP2015/053162, filed on Feb. 13, 2015.
Claims priority of application No. PA201470076 (DK), filed on Feb. 14, 2014.
Prior Publication US 2020/0407682 A1, Dec. 31, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61P 35/02 (2006.01); A61P 35/00 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C12N 2501/599 (2013.01); C12N 2510/00 (2013.01); Y02A 50/30 (2018.01)]

18 Claims

1. A method of preparing an immune cell for immunotherapy comprising:

(a) inactivating or mutating a gene encoding a CD38 antigen marker in an immune cell; and

(b) expressing in said immune cell a transgene encoding a chimeric antigen receptor (CAR) directed against said CD38 antigen marker.